Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
Harrow (Nasdaq: HROW) to Release Financial Results for Q4 and Year-End 2023, Host Conference Call on March 20, 2024
03/05/2024 - 07:00 AM
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on March 20, 2024
NASHVILLE, Tenn. --(BUSINESS WIRE)--
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 19, 2024, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com . Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Wednesday, March 20, 2024, to discuss the results and provide a business update.
Conference Call Details:
Date:
Wednesday, March 20, 2024
Time:
8:00 a.m. Eastern time
Participant Dial-in:
1-833-953-2434 (U.S. )
Replay Dial-in (Passcode 6766979):
(telephonic replay through March 27, 2024)
1-877-344-7529 (U.S. )
Webcast: (online replay through March 20, 2025)
harrow.com
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305397352/en/
Jamie Webb
jwebb@harrowinc.com
Source: Harrow, Inc.
Harrow will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 19, 2024, after the market close.
The conference call to discuss the results and provide a business update will be held on Wednesday, March 20, 2024, at 8:00 a.m. Eastern Time.
Investors can find the fourth quarter Letter to Stockholders in the 'Investors' section of Harrow's website, harrow.com.
Participants can dial 1-833-953-2434 (U.S.) or 1-412-317-5763 (International) to join the conference call on March 20, 2024, at 8:00 a.m. Eastern Time.
The telephonic replay with passcode 6766979 will be available through March 27, 2024. Participants can dial 1-877-344-7529 (U.S.) or 1-412-317-0088 (International) to access the replay.
Investors can access the online replay of the webcast through March 20, 2025, on harrow.com.
HROW Rankings
#1113 Ranked by Stock Gains
HROW Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
About HROW
harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas
